Here's what life science startups were named most promising at the recent Rice Alliance Texas Life Science Forum.. Getty Images

Houston hosted an annual meeting of the minds that included thoughtful discussions, presentations, panels, and startup pitches within the life science industry.

The Texas Life Science Forum, organized and hosted by the Rice Alliance and BioHouston, took place on November 6 at Rice University's Bioscience Research Collaborative. Throughout the day, over 50 life science startups pitched to the audience. At the end of the forum, 10 startups — most of which are based in Houston — were recognized as being the most promising.

Here's what life science startups you should be keeping an eye out for.

Abilitech Medical

abilitech

Photo via abilitechmedical.com

A St. Paul, Minnisota-based medical device company, Abilitech Medical develops assistive technology to Multiple sclerosis, Muscular Dystrophy, Parkinson's and stroke patients. The first product, Alibitech Assist, will be cleared by the FDA in 2020, with other devices to follow in 2022 and 2023.

AgilVax

agilvax

Photo via agilvax.com

Based in Albuquerque, New Mexico, AgilVax is a biopharmaceutical company that works with chemotherapy, checkpoint and KRAS inhibitors to fight various cancers. The company's AX09 is an immunotherapeutic that is headed for human clinical trials in 2020. Another product, M5, is a monoclonal antibody currently in preclinical trials.

Altoida

altoida

Photo via altoida.com

Altoida, based in Houston, has created a medical device that uses artificial intelligence and augmented reality to collect functional and cognitive data in patients to determine their risk Mild Cognitive Impairment from Alzheimer's Disease. The Altoida Neuro Motor Index has been cleared by the FDA and CE and detects cognitive decline with a 94 percent diagnostic accuracy six to 10 years ahead of the onset of symptoms.

ColubrisMX

Photo via Pexels

Houston-based ColubrisMX makes surgical robots specializing in minimally invasive and endoluminal surgeries. The company's team of engineers and surgeons works adjacent to the Texas Medical Center.

Cord Blood Plus

stem cell

Photo via Getty Images

Cord Blood Plus, based in Galveston, is working to commercialize its human umbilical cord blood stem cell technology. The company's primary mission is to use its research and treatment on breast cancer patients undergoing chemotherapy in order to prevent infections, speed up recovery, and shorten hospital stays.

CorInnova

CorInnova

Photo via CorInnova.com

Another Houston company, CorInnova is a medical device company that has developed a cardiac assist device to treat heart failure without many of the consequences from standard treatment. The device is able to self expand and gently compress the heart in sync with the heartbeat.

Mesogen

mesogen

Photo via Mesogen.com

Mesogen, which is based in The Woodlands, is in the business of using a patient's own cells to grow a human kidney for transplant. The tissue engineering technology allows for the creation of a kidney in less than a year with less risk of transplant rejection and a better quality of life over dialysis treatment.

Saranas

Courtesy of Saranas

Houston-based Saranas has created its Early Bird device to more quickly and more accurately detect bleeding in the human body. The company, which underwent successful clinical trials last year, recently received FDA clearance and launched the device in the United States.

Stream Biomedical

stream biomedical

Photo via streambiomedical.com

Stream Biomedical Inc. is tapping into a therapeutic protein that has proven to be neuroprotective and neuroreparative. The Houston company is aiming to apply the treatment in acute stroke cases and later for traumatic brain injury, Alzheimer's, and dementia cases.

VenoStent

Photo via venostent.com

Houston-based VenoStent has created a device that allows a successful stent implementation on the first try. VenoStent's SelfWrap is made from a shape-memory polymer that uses body heat to mold the stent into the vein-artery junction.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Texas foundation makes massive $180M donation to Galveston hospital

historic gift

The University of Texas Medical Branch in Galveston (UTMB) has accepted a staggering $130 million grant from the Sealy & Smith Foundation, which, combined with the $50 million that the foundation donated in 2025 to establish the Department of Cardiovascular Medicine, is the largest bequest in UTMB history.

The grant will go to grow cardiovascular imaging, diagnosis, and treatment at UTMB by establishing an inpatient cardiovascular hub on the sixth floor of Jennie Sealy Hospital. In honor of the donation, the department is being renamed the Sealy Heart and Vascular Institute.

“The Sealy & Smith Foundation has a long history of investing in initiatives that transform health care for the people of Galveston and beyond,” said John Kelso, president of The Sealy & Smith Foundation Board of Directors. “We believe the Sealy Heart & Vascular Institute has the potential to redefine cardiovascular care in our region by bringing together exceptional physicians, advanced technology, innovative research and a commitment to improving patient outcomes. This additional investment reflects our confidence in UTMB’s vision and our belief that the Institute will have a lasting impact for generations to come.”

The Sealy & Smith Foundation was established in 1922 by John Sealy II and his sister Jennie Sealy Smith. Bolstered by the Sealy fortune built on shipping, oil, banking, and railroads, the Foundation has donated more than $1.2 billion to UTMB over the last century, linking the family legacy to healthcare, teaching, and research. It was John Sealy Sr. who contributed the initial $50,000 to build a hospital on the island, which opened right alongside the new medical school created by the state legislator in what was then Texas's largest and most economically powerful city.

Since then, the Foundation has helped grow UTMB into a world-class hospital. The cardiovascular care especially is well-regarded, making the 2025 Newsweek/Statista List of America's Best Hospitals.

“This extraordinary investment reflects The Sealy & Smith Foundation’s unwavering commitment to improving health and advancing medical excellence,” said Dr. Jochen Reiser, UTMB president and CEO of the UTMB Health System. “The partnership between UTMB and The Sealy & Smith Foundation is very strong. Built on generations of shared vision and trust, it continues to redefine what an academic health system can achieve. Together, we are building one of the nation’s premier cardiovascular programs integrating exceptional patient care, groundbreaking research, innovation and world-class education to improve the lives of patients throughout Texas and beyond.”

---

This article originally appeared on CultureMap.com.